These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

400 related items for PubMed ID: 28254742

  • 1. Pirfenidone ameliorates murine chronic GVHD through inhibition of macrophage infiltration and TGF-β production.
    Du J, Paz K, Flynn R, Vulic A, Robinson TM, Lineburg KE, Alexander KA, Meng J, Roy S, Panoskaltsis-Mortari A, Loschi M, Hill GR, Serody JS, Maillard I, Miklos D, Koreth J, Cutler CS, Antin JH, Ritz J, MacDonald KP, Schacker TW, Luznik L, Blazar BR.
    Blood; 2017 May 04; 129(18):2570-2580. PubMed ID: 28254742
    [Abstract] [Full Text] [Related]

  • 2. Extracellular vesicles derived from mesenchymal stem cells prevent skin fibrosis in the cGVHD mouse model by suppressing the activation of macrophages and B cells immune response.
    Guo L, Lai P, Wang Y, Huang T, Chen X, Geng S, Huang X, Luo C, Wu S, Ling W, Huang L, Du X, Weng J.
    Int Immunopharmacol; 2020 Jul 04; 84():106541. PubMed ID: 32402950
    [Abstract] [Full Text] [Related]

  • 3. Murine sclerodermatous graft-versus-host disease, a model for human scleroderma: cutaneous cytokines, chemokines, and immune cell activation.
    Zhang Y, McCormick LL, Desai SR, Wu C, Gilliam AC.
    J Immunol; 2002 Mar 15; 168(6):3088-98. PubMed ID: 11884483
    [Abstract] [Full Text] [Related]

  • 4. Donor B-cell alloantibody deposition and germinal center formation are required for the development of murine chronic GVHD and bronchiolitis obliterans.
    Srinivasan M, Flynn R, Price A, Ranger A, Browning JL, Taylor PA, Ritz J, Antin JH, Murphy WJ, Luznik L, Shlomchik MJ, Panoskaltsis-Mortari A, Blazar BR.
    Blood; 2012 Feb 09; 119(6):1570-80. PubMed ID: 22072556
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. MicroRNA-17-92 is required for T-cell and B-cell pathogenicity in chronic graft-versus-host disease in mice.
    Wu Y, Schutt S, Paz K, Zhang M, Flynn RP, Bastian D, Sofi MH, Nguyen H, Dai M, Liu C, Chang YJ, Blazar BR, Yu XZ.
    Blood; 2018 Apr 26; 131(17):1974-1986. PubMed ID: 29530952
    [Abstract] [Full Text] [Related]

  • 7. Aberrant germinal center formation, follicular T-helper cells, and germinal center B-cells were involved in chronic graft-versus-host disease.
    Shao L, Lie AK, Zhang Y, Wong CH, Kwong YL.
    Ann Hematol; 2015 Sep 26; 94(9):1493-504. PubMed ID: 25963280
    [Abstract] [Full Text] [Related]

  • 8. Targeting Bcl-6 prevents sclerodermatous chronic graft-versus-host disease by abrogating T follicular helper differentiation in mice.
    Chen X, Wang Y, Huang X, Geng S, Li C, Zeng L, Huang L, Du X, Weng J, Lai P.
    Int Immunopharmacol; 2023 Apr 26; 117():109746. PubMed ID: 36827923
    [Abstract] [Full Text] [Related]

  • 9. Targeting PI3Kδ function for amelioration of murine chronic graft-versus-host disease.
    Paz K, Flynn R, Du J, Tannheimer S, Johnson AJ, Dong S, Stark AK, Okkenhaug K, Panoskaltsis-Mortari A, Sage PT, Sharpe AH, Luznik L, Ritz J, Soiffer RJ, Cutler CS, Koreth J, Antin JH, Miklos DB, MacDonald KP, Hill GR, Maillard I, Serody JS, Murphy WJ, Munn DH, Feser C, Zaiken M, Vanhaesebroeck B, Turka LA, Byrd JC, Blazar BR.
    Am J Transplant; 2019 Jun 26; 19(6):1820-1830. PubMed ID: 30748099
    [Abstract] [Full Text] [Related]

  • 10. Anti-CX3CL1 (fractalkine) monoclonal antibody attenuates lung and skin fibrosis in sclerodermatous graft-versus-host disease mouse model.
    Hasegawa T, Utsunomiya A, Chino T, Kasamatsu H, Shimizu T, Matsushita T, Obara T, Ishii N, Ogasawara H, Ikeda W, Imai T, Oyama N, Hasegawa M.
    Arthritis Res Ther; 2024 May 03; 26(1):94. PubMed ID: 38702742
    [Abstract] [Full Text] [Related]

  • 11. Notch signaling mediated by Delta-like ligands 1 and 4 controls the pathogenesis of chronic GVHD in mice.
    Radojcic V, Paz K, Chung J, Du J, Perkey ET, Flynn R, Ivcevic S, Zaiken M, Friedman A, Yan M, Pletneva MA, Sarantopoulos S, Siebel CW, Blazar BR, Maillard I.
    Blood; 2018 Nov 15; 132(20):2188-2200. PubMed ID: 30181175
    [Abstract] [Full Text] [Related]

  • 12. Anti-TGF-beta treatment prevents skin and lung fibrosis in murine sclerodermatous graft-versus-host disease: a model for human scleroderma.
    McCormick LL, Zhang Y, Tootell E, Gilliam AC.
    J Immunol; 1999 Nov 15; 163(10):5693-9. PubMed ID: 10553100
    [Abstract] [Full Text] [Related]

  • 13. Small-molecule BCL6 inhibitor effectively treats mice with nonsclerodermatous chronic graft-versus-host disease.
    Paz K, Flynn R, Du J, Qi J, Luznik L, Maillard I, MacDonald KP, Hill GR, Serody JS, Murphy WJ, Sage PT, Sharpe AH, Miklos D, Cutler CS, Koreth J, Antin JH, Soiffer RJ, Ritz J, Bradner JE, Melnick AM, Blazar BR.
    Blood; 2019 Jan 03; 133(1):94-99. PubMed ID: 30279226
    [Abstract] [Full Text] [Related]

  • 14. BET-bromodomain and EZH2 inhibitor-treated chronic GVHD mice have blunted germinal centers with distinct transcriptomes.
    Zaiken MC, Flynn R, Paz KG, Rhee SY, Jin S, Mohamed FA, Saha A, Thangavelu G, Park PMC, Hemming ML, Sage PT, Sharpe AH, DuPage M, Bluestone JA, Panoskaltsis-Mortari A, Cutler CS, Koreth J, Antin JH, Soiffer RJ, Ritz J, Luznik L, Maillard I, Hill GR, MacDonald KPA, Munn DH, Serody JS, Murphy WJ, Kean LS, Zhang Y, Bradner JE, Qi J, Blazar BR.
    Blood; 2022 May 12; 139(19):2983-2997. PubMed ID: 35226736
    [Abstract] [Full Text] [Related]

  • 15. Targeting the Retinoid X Receptor Pathway Prevents and Ameliorates Murine Chronic Graft-Versus-Host Disease.
    Thangavelu G, Zaiken MC, Mohamed FA, Flynn R, Du J, Rhee SY, Riddle MJ, Aguilar EG, Panoskaltsis-Mortari A, Sanders ME, Blazar BR.
    Front Immunol; 2022 May 12; 13():765319. PubMed ID: 35359939
    [Abstract] [Full Text] [Related]

  • 16. CSF-1-dependant donor-derived macrophages mediate chronic graft-versus-host disease.
    Alexander KA, Flynn R, Lineburg KE, Kuns RD, Teal BE, Olver SD, Lor M, Raffelt NC, Koyama M, Leveque L, Le Texier L, Melino M, Markey KA, Varelias A, Engwerda C, Serody JS, Janela B, Ginhoux F, Clouston AD, Blazar BR, Hill GR, MacDonald KP.
    J Clin Invest; 2014 Oct 12; 124(10):4266-80. PubMed ID: 25157821
    [Abstract] [Full Text] [Related]

  • 17. Targeted Rho-associated kinase 2 inhibition suppresses murine and human chronic GVHD through a Stat3-dependent mechanism.
    Flynn R, Paz K, Du J, Reichenbach DK, Taylor PA, Panoskaltsis-Mortari A, Vulic A, Luznik L, MacDonald KK, Hill GR, Nyuydzefe MS, Weiss JM, Chen W, Trzeciak A, Serody JS, Aguilar EG, Murphy WJ, Maillard I, Munn D, Koreth J, Cutler CS, Antin JH, Ritz J, Waksal SD, Zanin-Zhorov A, Blazar BR.
    Blood; 2016 Apr 28; 127(17):2144-54. PubMed ID: 26983850
    [Abstract] [Full Text] [Related]

  • 18. Inhibition of the IRE-1α/XBP-1 pathway prevents chronic GVHD and preserves the GVL effect in mice.
    Schutt SD, Wu Y, Tang CH, Bastian D, Nguyen H, Sofi MH, Zhang M, Liu C, Helke K, Wilson C, Schnapp LM, Del Valle JR, Hu CC, Yu XZ.
    Blood Adv; 2018 Feb 27; 2(4):414-427. PubMed ID: 29483082
    [Abstract] [Full Text] [Related]

  • 19. Fibrotic and sclerotic manifestations of chronic graft-versus-host disease.
    Kitko CL, White ES, Baird K.
    Biol Blood Marrow Transplant; 2012 Jan 27; 18(1 Suppl):S46-52. PubMed ID: 22226112
    [No Abstract] [Full Text] [Related]

  • 20. CCL1 blockade alleviates human mesenchymal stem cell (hMSC)-induced pulmonary fibrosis in a murine sclerodermatous graft-versus-host disease (Scl-GVHD) model.
    Lim JY, Ryu DB, Kim TW, Lee SE, Park G, Yoon HK, Min CK.
    Stem Cell Res Ther; 2020 Jun 26; 11(1):254. PubMed ID: 32586381
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.